↓ Skip to main content

Dove Medical Press

Article Metrics

Clinical utility of ramucirumab in advanced gastric cancer

Overview of attention for article published in Biologics: Targets & Therapy, September 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
40 Mendeley
Title
Clinical utility of ramucirumab in advanced gastric cancer
Published in
Biologics: Targets & Therapy, September 2015
DOI 10.2147/btt.s62777
Pubmed ID
Authors

John Zalcberg, Katrin Sjoquist, Matthew Chan

Abstract

Gastric cancer is currently the third most common cause of cancer deaths worldwide. Prognosis remains poor with most patients presenting with advanced or metastatic disease. A better understanding of angiogenesis has led to the investigation of drugs that inhibit the vascular endothelial growth factor (VEGF) pathway including anti-VEGF antibody therapy (eg, bevacizumab), inhibitors of angiogenic receptor tyrosine kinases (eg, sunitinib, sorafenib, apatinib, regorafenib), and inhibitors of vascular endothelial growth factor receptors (VEGFRs) (eg, ramucirumab). Ramucirumab, a VEGFR-2 inhibitor, is the first anti-angiogenic agent approved by the US Food and Drug Administration for use in the treatment of advanced gastric cancers. This review will focus on the clinical utility and potential use of ramucirumab in advanced gastric cancer.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 40 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 9 23%
Student > Bachelor 5 13%
Researcher 5 13%
Student > Postgraduate 4 10%
Student > Doctoral Student 3 8%
Other 8 20%
Unknown 6 15%
Readers by discipline Count As %
Medicine and Dentistry 17 43%
Biochemistry, Genetics and Molecular Biology 3 8%
Pharmacology, Toxicology and Pharmaceutical Science 3 8%
Agricultural and Biological Sciences 3 8%
Nursing and Health Professions 2 5%
Other 5 13%
Unknown 7 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 September 2015.
All research outputs
#3,013,100
of 6,392,724 outputs
Outputs from Biologics: Targets & Therapy
#57
of 132 outputs
Outputs of similar age
#108,109
of 200,763 outputs
Outputs of similar age from Biologics: Targets & Therapy
#2
of 6 outputs
Altmetric has tracked 6,392,724 research outputs across all sources so far. This one is in the 29th percentile – i.e., 29% of other outputs scored the same or lower than it.
So far Altmetric has tracked 132 research outputs from this source. They receive a mean Attention Score of 2.2. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 200,763 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.